>>**Entry Name: 9-Aminocamptothecin**
Synonym(s): 10-Amino-4-ethyl-4-hydroxy-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoline-3,14(4*H*,12*H*)-dione, $_{9Cl}$. NSC 603071



(*S*)-*form*

Molecular Formula: $C_{20}H_{17}N_3O_4$
Molecular Weight: 363.372
Accurate Mass: 363.121907
Percentage Composition: C 66.11%; H 4.72%; N 11.56%; O 17.61%
Biological Use/Importance: Topoisomerase I inhibitor. Antineoplastic agent
Other Data: Relat. to Camptothecin CFK58-X

>>**Variant:** (*R*)-form

CAS Registry Number: 151593-95-2
Molecular Formula: $C_{20}H_{17}N_3O_4$
Molecular Weight: 363.372
Accurate Mass: 363.121907
Percentage Composition: C 66.11%; H 4.72%; N 11.56%; O 17.61%
Physical Description: Yellow solid
Optical Rotation: $[\alpha]_D^{22}$+12 (c, 0.26 in DMF)

>>**Variant:** (*S*)-form

CAS Registry Number: 91421-43-1
Molecular Formula: $C_{20}H_{17}N_3O_4$
Molecular Weight: 363.372
Accurate Mass: 363.121907
Percentage Composition: C 66.11%; H 4.72%; N 11.56%; O 17.61%
Physical Description: Orange-yellow amorph. powder ($MeOH/CHCl_3$)
Melting Point: Mp 300° (dec.)
Optical Rotation: $[\alpha]_D^{23}$+16 (c, 0.05 in $CHCl_3$/MeOH). $[\alpha]_D^{21}$–13 (c, 0.29 in DMF)
Other Data: Pharmacol. active isomer

>>**Variant:** (±)-form
Synonym(s): NSC 629971

CAS Registry Number: 130194-90-0
Molecular Formula: $C_{20}H_{17}N_3O_4$
Molecular Weight: 363.372
Accurate Mass: 363.121907
Percentage Composition: C 66.11%; H 4.72%; N 11.56%; O 17.61%
Physical Description: Tan-orange solid ($MeOH/CHCl_3$)
UV: [neutral] λ_{max} 238 (ε 6100); 256 (ε 3800) (MeOH) (Berdy)

References:

Japan. Pat., 1984, *Yakult Honsha*, 59 51 289; *CA*, **101**, 91319d, *(synth)*
Wani, M.C. *et al.*, *J. Med. Chem.*, 1986, **29**, 2358-2363; 1993, **36**, 2689-2700, *(synth, pmr, ir, pharmacol)*
Hinz, H.R. *et al.*, *Cancer Res.*, 1994, **54**, 3096-3100, *(pharmacokinet)*
Takimoto, C.H. *et al.*, *J. Chromatogr., B: Biomed. Appl.*, 1994, **655**, 97-104, *(hplc)*
Rubin, E. *et al.*, *Clin. Cancer Res.*, 1995, **1**, 269-276, *(clin trial, pharmacokinet)*
Cabri, W. *et al.*, *Tet. Lett.*, 1995, **36**, 9197-9200, *(synth)*
Potmesil, M. *et al.*, *Ann. N.Y. Acad. Sci.*, 1996, **803**, 231-246; 247-255, *(rev, pharmacol, clin trial)*
Robinson, C. *et al.*, *Drugs of the Future*, 1996, **21**, 881-889, *(rev, synth, pharmacol, tox)*
Dahut, W. *et al.*, *J. Clin. Oncol.*, 1996, **14**, 1236-1244, *(clin trial, pharmacol)*
Erickson-Miller, C.L. *et al.*, *Cancer Chemother. Pharmacol.*, 1997, **39**, 467-472, *(pharmacol)*
Loos, W.J. *et al.*, *J. Chromatogr., B: Biomed. Appl.*, 1997, **694**, 435-441, *(hplc)*
Mani, S. *et al.*, *Cancer Chemother.*, 1998, **42**, 84-87, *(clin trial)*